SpringerLink
Log in

Genetic variation of CYP2C9 gene and its correlation with cardiovascular disease risk factors

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

The major enzyme that is responsible for Sulfonylureas (SUs) metabolism is hepatic cytochrome P-450 2C9 (CYP2C9). It is encoded by the polymorphic gene CYP2C9, which has many allelic variants, among those the CYP2C9*2 and CYP2C9*3 are the most common and clinically significant allelic variations. People with diabetes mellitus type 2 (T2DM) are more likely to develop cardiovascular disease (CVD), and their risk of dying from it is more than two times higher than that of people without the condition. The purpose of this study was to evaluate the association of genetic variations in the CYP2C9 gene with cardiovascular risk factors by investigating CYP2C9*1, *2, *3, *5, *11, and *13 allelic variants.

Methods and results

A total of 226 participants were enrolled in the current case-control study. Allele-specific amplification- PCR (ASA-PCR) was used to determine the allele of different variations and the results were confirmed by sequencing. The findings of this study showed the presence of the CYP2C9*2 allele in the T2DM group does not differ from its percentage in the control group. Also, CYP2C9*3 allele frequencies identified by Hardy-Weinberg equilibrium (HWE) analysis law were not significant, p = 0.6593 and 0.5828 in T2DM and control groups. There is no statistically significant difference between the control and diabetes groups involving the distribution of CYP2C9 alleles and CYP2C9*5, *11, and *13 polymorphisms were absent in the Iraqi population. No carrier for the CYP2C9*3 homozygous state was found in both groups.

Conclusions

According to these results T2DM patients with the CYP2C9*2 and *3 variants have an increased risk of develo** hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are available from the authors.

References

  1. Nelson DR, Nebert DW (2018) Cytochrome P450 (CYP) gene superfamily. ELS. John Wiley and Sons, Ltd, pp 1–19

  2. Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE (2018) The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther 103:399–401

    Article  CAS  PubMed  Google Scholar 

  3. Gao B, Tan T, Cao X, Pan M, Yang C, Wang J, Shuai Z, **a Q (2022) Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions. BMC Med Genomics 15:23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Nizamuddin S, Dubey S, Singh S, Sharma S, Machha P, Thangaraj K (2021) CYP2C9 variations and their pharmacogenetic implications among diverse south Asian populations. Pharmacogenomics Pers Med 14:135–147

    Google Scholar 

  5. Zhou Y, Nevosadová L, Eliasson E, Lauschke VM (2023) Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. Hum Genomics 17:15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dean L (2012) Lesinurad Therapy and CYP2C9 genotype. Med Genet Summ, 1–10

  7. Lee HW, Lee J, Jegal Y, Kim W, Lee K, Jang J, Shin G, Yoon R (2012) Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. J Clin Pharm Ther 37:105–111

  8. Liu Q, Hu F, Zeng J, Ma L, Yan S, Li C, Tian H, Gong Y (2023) Islet function changes of post-glucose-challenge relate closely to 15 years mortality of elderly men with a history of hyperglycemia. Heliyon 9:e14100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio DA, Davies MJ (2020) 2019 Update to: management of hyperglycemia in type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43:487–493

    Article  CAS  PubMed  Google Scholar 

  10. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark A, Metzger BE, Nathan DM, Kirkman MS (2023) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 69:808–868

    Article  PubMed  Google Scholar 

  11. Buzková H, Pechandová K, Danzig V, Vareka T, Perlik F, Zak A, Slanar O (2012) Lipid-lowering effect of fluvastatin about cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monitor Int Med J Exp Clin Res 18:CR512–CR517

    Article  Google Scholar 

  12. Spohn G, Geisen C, Luxembourg B, Sittinger K, Seifried E, Bönig H (2011) Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genoty** assay for vitamin K antagonist pharmacogenomics molecular diagnosis and therapy. 15:13–19

  13. Smolik S, Moric-Janiszewska E, Węglarz L (2014) CYP2C9 gene polymorphism in the pharmacological treatment of long qt patients. Acta Pol Pharm Drug Res 71:1103–1106

    Google Scholar 

  14. Veras RP (2014) Design and implementation of a novel genoty** assay for CYP2C9, CYP4F2 and GGCX polymorphisms to predict warfarin maintenance dose. Postgraduate Dissertations in M.Sc. 19–50

  15. Zuo J, **a D, Jia L, Guo T (2012) Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie 67:639–644

    CAS  PubMed  Google Scholar 

  16. Al-Attar MM, Al-Awadi SJ, Abdulfattah SY (2022) Role of miRNA-27a and miRNA-224 in posttranscriptional regulation of PCSK9 gene in Iraqi patient with coronary artery Disease. Hum Gene 34:201121

    Article  CAS  Google Scholar 

  17. Glover T, Mitchell K (2008) An introduction to Biostatistics, 2nd edn. Waveland Press Inc, Long Grove

  18. Forthofer RN, Lee ES (2014) Introduction to biostatistics: a guide to design, analysis, and discovery. 2nd ed. Elsevier, Amsterdam, pp 1–602

  19. Al-Attar MM, Al-Awadi SJ, Abdulfattah SY (2023) Gene expression and methylation levels of PCSK9 gene in Iraqi patients with coronary artery Disease. Baghdad Sci J 34:2078–8665

    Google Scholar 

  20. Bae JW, Choi CI, Jang CG, Lee SY (2011) Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 71:550–555

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ (2010) Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11:781–791

    Article  CAS  PubMed  Google Scholar 

  22. Szumilas M (2010) Explaining odds ratios. J Can Acad Child Adolesc Psychiatry 19:227–229

    PubMed  PubMed Central  Google Scholar 

  23. Buzoianu AD, Trifa AP, Mureşanu DF, Crişan S (2012) Analysis of CYP2C9*2, CYP2C9*3, and VKORC1 -1639 G > A polymorphisms in a population from South-Eastern Europe. J of Cellu and Molec Med 16:2919–2924

    Article  CAS  Google Scholar 

  24. Dorji PW, Wangchuk S, Boonprasert K, Tarasuk M, Na-Bangchang K (2019) Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population. Drug Metabolism and Personalized Therapy 34:1–14

    Article  Google Scholar 

  25. Griffiths AJF, Miller JH (2020) An Introduction to Genetic Analysis (12th edition). New York, NY: W.H. Freeman and Company, 2015

  26. Arici M, Özhan G (2017) CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. Saudi Pharm J 25:376–380

    Article  PubMed  Google Scholar 

  27. Marjani A, Gharanjik AM (2018) Genetic polymorphism of CYP2C9 among Sistani Ethnic Group in Gorgan. Indian J Clin Biochem 33:208–213

    Article  CAS  PubMed  Google Scholar 

  28. Mirghani RA, Chowdhary G, Elghazali G (2011) Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi Population. Basic and Clinical Pharmacology and Toxicology 109:111–114

    Article  CAS  PubMed  Google Scholar 

  29. Yousef AM, Bulatova NR, Newman W, Hakooz N, Ismail S, Qusa H, Zahran F, Ababneh NA, HasanF, Zaloom I, Khayat G, Al-Zmili R, Naffa R, Al-Diab O (2012) Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9, and CYP2C19) in the Jordanian population. Molecular Biology Reports, 39:9423–9433

  30. Zhou S, Zhou Z, Huang M (2010) Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278:165–188

    Article  CAS  PubMed  Google Scholar 

  31. Daly AK, Rettie AE, Fowler DM, Miners JO (2018) Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med 8:1–31

    Article  Google Scholar 

  32. Jaja C, Patel N, Scott SA, Gibson R, Kutlar A (2014) CYP2C9 allelic variants and frequencies in a pediatric sickle cell Disease cohort: implications for NSAIDs pharmacotherapy. Clin Transl Sci 7:396–401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Elfaki I, Mir R, Abu-Duhier FM, Jha CK, Ahmad Al-Alawy AI, Babakr AT, Habib SA (2020) Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 gene variations with type 2 Diabetes: a case-control study. Curr Drug Metab 21:1152–1160

    Article  CAS  PubMed  Google Scholar 

  34. Semiz S, Dujic Tanja BO, Prnjavorac B, Bego T, Malenica M, Causevic JMA (2010) Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 Diabetes Mellitus. Bosnian J Basic Med Sci 10:288–291

    Google Scholar 

  35. Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmöller J, Kirchheiner J (2005) Association between CYP2C9 slow metabolizer genotypes and severe hypoglycemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 60:103–106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. John M, Kalra S, Nair T (2020) Modern sulphonylureas and cardiovascular adverse effects: will CAROLINA put an end to the controversy? Indian Heart J 72:312–315

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tinker A, Aziz Q, Thomas A (2014) The role of ATP-sensitive potassium channels in cellular function and protection in the cardiovascular system. Br J Pharmacol 171:12–23

    Article  CAS  PubMed  Google Scholar 

  38. Salam RFA, Zeyada R, Osman NA (2014) Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 Diabetes Mellitus patients. Comp Clin Pathol 23:341–346

    Article  Google Scholar 

  39. Koren S, Koren R (2015) Any polymorphisms of CYP2C9 affects the biochemical Profile of Diabetic patients receiving glibenclamide. Clin Med Biochemistry: Open Access 01:1–4

    Article  Google Scholar 

Download references

Acknowledgements

The authors are grateful to all staff members in Al-Salam Hospital and Al-Wafaa Center for Diabetes and Endocrinology in Mosul/ Iraq for their facilities, which helped improve the quality of this work, as well as all study participants.

Funding

The authors reported there is no funding associated with the work featured in this article.

Author information

Authors and Affiliations

  1. Department of Anatomy, Faculty of Medicine, Ninevah University, Mosul, Iraq

    Ghada S. Rasool

  2. Department of Molecular and Medical Genetics Technologies, College of Biotechnology, Al-Nahrain University, Baghdad, Iraq

    Salwa J. Al-Awadi & Asmaa A. Hussien

  3. Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq

    Marwa M. Al-Attar

Authors
  1. Ghada S. Rasool
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salwa J. Al-Awadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asmaa A. Hussien
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marwa M. Al-Attar
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GSR: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Data curation, Writing – original draft. SJA, AAH: Supervision, Project administration, Methodology, Formal analysis, Investigation, Data curation. MA: Formal analysis, Investigation, Data curation, Writing – original draft.

Corresponding author

Correspondence to Marwa M. Al-Attar.

Ethics declarations

Ethics approval

This study was approved by the Ethics Committee of (Ministry of Health/Baghdad, Iraq (decree order 1061/ 12-1-2020).

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rasool, G.S., Al-Awadi, S.J., Hussien, A.A. et al. Genetic variation of CYP2C9 gene and its correlation with cardiovascular disease risk factors. Mol Biol Rep 51, 105 (2024). https://doi.org/10.1007/s11033-023-09151-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11033-023-09151-4

Keywords

Search

Navigation